Is Mereo BioPharma Group PLC ADR (MREO) undervalued? · $48.7M cap
Mereo BioPharma Group PLC ADR (MREO) is a biotechnology company listed on US.
This page asks whether Mereo BioPharma Group PLC ADR (MREO) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported MREO revenue for 2026-06-30 was $0. Net income was -$7.0M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. MREO currently screens at market cap $48.7M.
MREO currently screens at market cap $48.7M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new MREO 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare MREO to the stock page model before you treat a low multiple as a gift.
Not investment advice.